ATE368683T1 - Schwefel analoge von 21-hydroxy-6,19- oxidoprogesteronen (21oh-6op) zur behandlung von glucocorticoidüberschuss - Google Patents

Schwefel analoge von 21-hydroxy-6,19- oxidoprogesteronen (21oh-6op) zur behandlung von glucocorticoidüberschuss

Info

Publication number
ATE368683T1
ATE368683T1 AT01969729T AT01969729T ATE368683T1 AT E368683 T1 ATE368683 T1 AT E368683T1 AT 01969729 T AT01969729 T AT 01969729T AT 01969729 T AT01969729 T AT 01969729T AT E368683 T1 ATE368683 T1 AT E368683T1
Authority
AT
Austria
Prior art keywords
oxidoprogesterone
hydroxy
treatment
glucocorticoid excess
sulfur analogue
Prior art date
Application number
AT01969729T
Other languages
English (en)
Inventor
Gerardo Burton
Carlos Lantos
Adriana Veleiro
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of ATE368683T1 publication Critical patent/ATE368683T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0073—Sulfur-containing hetero ring
    • C07J71/0078—Sulfur-containing hetero ring containing only sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01969729T 2000-09-18 2001-09-17 Schwefel analoge von 21-hydroxy-6,19- oxidoprogesteronen (21oh-6op) zur behandlung von glucocorticoidüberschuss ATE368683T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00119495 2000-09-18

Publications (1)

Publication Number Publication Date
ATE368683T1 true ATE368683T1 (de) 2007-08-15

Family

ID=8169775

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01969729T ATE368683T1 (de) 2000-09-18 2001-09-17 Schwefel analoge von 21-hydroxy-6,19- oxidoprogesteronen (21oh-6op) zur behandlung von glucocorticoidüberschuss

Country Status (14)

Country Link
US (2) US7053228B2 (de)
EP (1) EP1330468B1 (de)
JP (1) JP2004509132A (de)
AT (1) ATE368683T1 (de)
AU (1) AU8988901A (de)
CA (1) CA2419887C (de)
CY (1) CY1107756T1 (de)
DE (1) DE60129725T2 (de)
DK (1) DK1330468T3 (de)
ES (1) ES2288987T3 (de)
IL (2) IL154775A0 (de)
PT (1) PT1330468E (de)
SI (1) SI1330468T1 (de)
WO (1) WO2002022647A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1330468T3 (da) * 2000-09-18 2007-11-05 Serono Lab Svovlanaloger af 21 hydroxy-6,19-oxido-progesteron (21OH 6OP) til behandling af overskud af glucocorticoider
US7071328B2 (en) * 2000-09-18 2006-07-04 Applied Research System Ars Holding N.V. Method for the preparation of 21-hydroxy-6,19-oxidoprogesterone (21 oh-6op)
CN102190607A (zh) * 2010-03-15 2011-09-21 北京化工大学 一种农药除草剂中间体乙磺酰基乙腈的绿色合成方法
EP2413115A1 (de) * 2010-07-30 2012-02-01 Technische Universiteit Eindhoven Erzeugen eines Steuersignals aus akustischen Daten

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4910191A (en) * 1988-06-28 1990-03-20 Merrell Dow Pharmaceuticals Inc. 19-substituted progesterone derivatives useful as 19-hydroxylase inhibitors
CZ307995A3 (en) * 1993-05-24 1996-10-16 Immunex Corp Ligands for flt3 receptors
PT903148E (pt) 1997-09-21 2002-02-28 Schering Corp Terapia de combinacao para a erradicacao de rna de hcv detectavel em doentes tendo infeccao cronica pelo virus da hepatite c
EP0903146A1 (de) * 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (21-0H-60P) als ANitoglucocortikoid
CN1173703C (zh) * 1999-04-23 2004-11-03 里奥药物制品有限公司 药物组合物
DK1330468T3 (da) 2000-09-18 2007-11-05 Serono Lab Svovlanaloger af 21 hydroxy-6,19-oxido-progesteron (21OH 6OP) til behandling af overskud af glucocorticoider
US7071328B2 (en) 2000-09-18 2006-07-04 Applied Research System Ars Holding N.V. Method for the preparation of 21-hydroxy-6,19-oxidoprogesterone (21 oh-6op)

Also Published As

Publication number Publication date
WO2002022647A1 (en) 2002-03-21
IL154775A0 (en) 2003-10-31
CA2419887C (en) 2009-11-10
US20040029846A1 (en) 2004-02-12
DE60129725T2 (de) 2007-12-06
CY1107756T1 (el) 2013-09-04
PT1330468E (pt) 2007-09-13
EP1330468A1 (de) 2003-07-30
US7479486B2 (en) 2009-01-20
CA2419887A1 (en) 2002-03-21
ES2288987T3 (es) 2008-02-01
EP1330468B1 (de) 2007-08-01
US7053228B2 (en) 2006-05-30
IL154775A (en) 2010-12-30
DK1330468T3 (da) 2007-11-05
AU8988901A (en) 2002-03-26
US20050222104A1 (en) 2005-10-06
JP2004509132A (ja) 2004-03-25
DE60129725D1 (de) 2007-09-13
SI1330468T1 (sl) 2007-10-31

Similar Documents

Publication Publication Date Title
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
ATE245416T1 (de) Neue fettanaloge zur behandlung von diabetes
DE69914726D1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
SI2298338T1 (sl) Laktoferinski sestavki in postopki za zdravljenjekožnih ran
ATE202706T1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
DE69726724D1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
ATE309775T1 (de) Die verwendung von prostaglandin f analoga zur herstellung von zusammensetzungen für die behandlung von haarausfall.
DE69429450D1 (de) Die verwendung von angiotensin iii und seiner analoge für die gewebeheilung
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
ATE337780T1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
AR023008A1 (es) 21-hidroxi-6,19-oxidoprogesterona (21oh-6op) para tratar el exceso de glucocorticoides
ATE262895T1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
ATE458057T1 (de) Varianten der faktor-vii- oder -viia-gla-domäne
ATE292976T1 (de) Verwendung von angiotensin analogen zur herstellung eines arzneimittels zur steigerung des ueberlebens der weissen blutzellen und mobilisierung von haematopoietischen stammzellen nach einer chemotherapeutischen behandlung
ATE258791T1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
ATE138567T1 (de) Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen
DE69825279D1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
ATE422892T1 (de) Verwendung von hyaluronsäure zur herstellung von zusammensetzungen zur behandlung rekurrenten aphthen in der mundhöhle
DE60215649D1 (de) Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
CY1107756T1 (el) Αναλογα θειου της 21-υδροξυ-6, 19-οξειδοπρογεστερονης (21oh-6οp) για τη θεραπεια πλεονασματος γλυκοκορτικοειδων
ATE526056T1 (de) Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes
ATE427956T1 (de) Ckrox-peptide und ihre analoge zur behandlung von hautalterung
DK1189627T3 (da) Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1330468

Country of ref document: EP

EEFA Change of the company name